Generic Tiazac Approved for Hypertension

Generic Tiazac

Andrx Corporation has announced that the FDA has approved the marketing of its Abbreviated New Drug Application for TaztiaTM (diltiazem HCl). The extended-release capsules are bioequivalent to Tiazac® (Biovail). This product, a calcium-channel blocker, is indicated to treat hypertension and chronic stable angina. The capsules will be available in strengths of 120, 180, 240, 300, and 360 mg.